Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline

Hagens Berman notified Aardvark Therapeutics investors of a pending securities class action covering shares bought in or traceable to the February 13, 2025 IPO and securities acquired from February 13, 2025 through May 14, 2026. The notice signals potential litigation and reputational risk for Nasdaq-listed AARD, though it provides no allegations, claimed damages, or financial impact details.

Analysis

This is not, by itself, a fundamental catalyst: plaintiff-firm notices are often derivative of prior price declines and do not establish liability, damages, or a near-term cash cost. The market-relevant issue is whether the underlying allegations lead to an amended complaint that survives dismissal, discovery of internal trial/launch communications, or an SEC inquiry; those events can materially increase D&O exposure and management distraction over a 6-18 month horizon.

For a recently public biotech, litigation can compound the IPO discount rather than drive operating value directly. AARD's multiple and financing capacity are likely more sensitive to clinical execution, regulatory milestones, cash runway, and future equity issuance than to this notice. The second-order risk is that legal overhang narrows the institutional buyer base ahead of a capital raise, raising dilution and lowering the probability of an at-the-market financing being absorbed cleanly.

Consensus may overreact if the shares decline solely on the filing announcement: securities suits frequently settle within insurance limits or are dismissed, while an early-stage biotech's enterprise value is principally a probability-weighted asset valuation. Conversely, a sustained drawdown is justified only if allegations identify a previously undisclosed clinical, safety, commercialization, or disclosure issue that changes the probability of approval or implies management credibility impairment. Until the complaint and alleged corrective disclosures are reviewed, there is no high-conviction directional trade.

Key Decisions for Investors

• Do not initiate a standalone AARD short on this notice; reassess only after the complaint is filed and identify whether allegations involve verifiable clinical/regulatory facts rather than generic IPO disclosure claims.
• For existing long exposure, reduce position size or hedge into the next financing/clinical catalyst if cash runway is below 12-18 months; litigation-driven institutional demand weakness can increase equity dilution even if ultimate legal damages are immaterial.
• Set an alert for dismissal-denial, SEC inquiry, reserve/insurance-disclosure changes, or a downward revision to clinical/regulatory guidance over the next 1-6 months. Any of these would validate a credibility-risk short thesis; dismissal or unchanged milestone guidance would falsify it.
• If AARD sells off materially without new fundamental disclosure, consider only a small event-driven long after confirming cash runway and lead-asset milestone timing; target a rebound to the pre-notice trading range, with a stop on new adverse clinical or regulatory information.